Brought to you by 
Ambrx gets $55mm with Series C financing
17 Aug 2006
Executive Summary
Ambrx (optimizes existing protein therapeutics) raised $55mm in a Series C financing led by new investor Apposite. Other first-time backers Glynn Ventures, the Dow Employees' Pension Plan, Scottish Widows Investment, and Union Carbide Employees' Pension Plan were joined by returning shareholders Tavistock Life Sciences, Maverick Capital, 5AM Ventures, Versant Ventures, Aravis Ventures, CMEA Ventures, and Roche Venture Fund. The company will use part of the funds to expand its ReCODE platform for modifying proteins. A member of Apposite has taken a seat on Ambrx's board.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Large Molecule
- Synthesis Technologies, Production Processes
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Ambrx gets $55mm with Series C financing
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice